Virginia Budgets $15M for Medicaid Sickle Cell Gene Therapy Coverage
Virginia lawmakers allocated nearly $15 million over two years to help the state Medicaid program cover gene therapy treatments for sickle cell disease patients. The funding connects to a federal payment model designed to help Medicaid programs manage the high cost of cell and gene therapies. The initiative aims to improve patient access to these treatments, which can cost over $2 million per patient. Providers indicated the funding could reduce barriers to obtaining complex gene therapy services through Medicaid.
This state appropriation demonstrates one approach to financing high-cost specialty therapies within Medicaid budgets and may influence how other states structure coverage for emerging gene therapies.
Managed Care · Finance
You might also like